CRISPR gene therapy baby thriving after world-first personalized treatment for rare disease

When a Pennsylvania newborn faced a life-threatening metabolic defect, doctors at the Children’s Hospital of Philadelphia moved quickly to try an unprecedented approach: a tailored CRISPR-based gene therapy aimed at fixing the child’s specific genetic error. The result is an evolving success story — a baby now eating more normally and off some medications after receiving a bespoke gene-editing treatment.

The case represents a landmark in personalized medicine, where researchers retooled advanced CRISPR techniques to correct a single patient’s mutation. Clinicians and scientists involved say the work could serve as a model for treating other ultra-rare genetic disorders that currently lack practical, standardized cures.

Why this newborn needed a genetic fix: understanding CPS1 deficiency

The infant, known publicly as KJ, was born with a severe form of carbamoyl phosphate synthetase 1 deficiency (CPS1 deficiency), a rare metabolic condition that prevents the liver from converting toxic ammonia into urea for safe excretion. Ammonia accumulates as the body breaks down protein, and without CPS1 activity this buildup can cause rapid and irreversible brain or liver damage.

Standard management options for infants with CPS1 deficiency include strict low-protein diets and medicines that help remove nitrogen, but these measures are often temporary bridges to liver transplantation. For very young infants, the risks and logistical challenges of a transplant can be prohibitive, leaving families with few viable options.

How clinicians designed a one-off CRISPR treatment for a single patient

A team led by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru at Children’s Hospital of Philadelphia turned to precision genome editing to target the exact CPS1 variant affecting KJ. Their method did not rely on off-the-shelf therapies; instead, they designed a custom base-editing construct and manufactured a personalized dose intended only for this child’s genetic change.

Key steps in the personalized therapy process

• Identify the precise mutation in the CPS1 gene responsible for the metabolic block.
• Design a base editor — a CRISPR-derived tool that can change individual DNA bases without cutting both strands.
• Package the editor into lipid nanoparticles optimized for delivery to liver cells.
• Run safety and manufacturing checks under tightly controlled timelines to prepare clinical-grade doses.

The team’s work was supported by the NIH-funded Somatic Cell Genome Editing Consortium, which has been advancing tools and delivery strategies for somatic (non-reproductive) gene editing. Unlike the two CRISPR therapies that have received broad regulatory approval and target more prevalent conditions, this intervention was created and scaled specifically for one infant’s rare mutation.

Delivery method: lipid nanoparticles and liver-targeted base editing

Rather than using viral vectors, the researchers employed lipid nanoparticles (LNPs) to ferry the base editor to liver cells. LNPs have become an increasingly important delivery vehicle for nucleic acid therapies because they can be manufactured quickly and modified to accumulate in particular tissues.

Base editing was chosen to precisely change the defective DNA letter in CPS1 without creating double-strand breaks, which can carry higher risks of unintended effects. The combination of base editor plus LNP delivery was tailored to correct the enzyme deficiency at its source in the liver.

Treatment timeline and early clinical results

• Design and manufacturing: weeks to months of rapid development after the patient’s mutation was characterized.
• First infusion: late February 2025, when the infant received the initial dose of the experimental gene-editing therapy.
• Follow-up doses: subsequent infusions administered in March and April 2025 as part of a planned regimen and monitoring protocol.

According to the team’s report in the New England Journal of Medicine, KJ received three doses and did not experience observable adverse effects from the treatment. Within weeks to months, clinicians were able to reduce KJ’s dependence on nitrogen-scavenging drugs and cautiously reintroduce some dietary protein — outcomes that signal meaningful improvement in metabolic control.

The therapy did not produce detectable side effects in the short term, and KJ’s family has expressed cautious optimism about the progress and the broader potential of this approach.

Family perspective and ethical considerations

KJ’s parents, Nicole and Kyle Muldoon, elected to pursue the experimental route after weighing the risks and potential benefits. They placed their trust in the CHOP team’s proposal with the hope that the intervention could help their son now and pave the way for other families facing similar genetic rarities.

Physicians emphasize that while the case marks a promising proof of concept, individualized gene-editing treatments raise complex ethical, regulatory, and access issues. Personalized therapies can be costly and technically demanding, and producing them quickly in a safe, ethical manner requires close collaboration among clinicians, researchers, regulators, and patients’ families.

Broader implications: scaling personalized CRISPR for ultra-rare diseases

Most current CRISPR treatments approved or in late-stage trials are aimed at conditions affecting thousands or tens of thousands of people. For the millions worldwide with ultra-rare genetic disorders, a scalable method to produce individualized gene-editing therapies would be transformative.

The CHOP team’s experience suggests one possible pathway: using modular editing platforms (like base editors), nonviral delivery systems (like LNPs), and streamlined manufacturing pipelines to create patient-specific doses more rapidly. Still, extensive follow-up, broader safety data, and regulatory frameworks tailored to individualized approaches will be needed before this strategy can help many patients.

Research on KJ continues — clinicians will monitor his metabolic health, liver function, and neurodevelopment over the long term to track durability and safety of the correction. The case adds to a growing body of work showing that highly targeted genome editing can be converted from lab concept to bedside intervention in exceptional circumstances.

You might also like:

• Gene therapy restores vision in 6-year-old Saffie with rare blindness
• Cancer-fighting cells engineered in patients’ bodies for the first time
• Bubble boy disease: babies still appear cured after long-term follow-up
• Cancer survival rates reach 70% after 20 years of research
• Cancer vaccine reduces melanoma risk 49% after five years

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.